GlaxoSmithKline shingles vaccine candidate proves 97.2% effective
Primary endpoint analysis demonstrated that administering scheduled two doses of HZ/su decreased the chances of herpes zoster by 97.2 percent when compared with the placebo. The efficiency of the vaccine was maintained throughout the age groups involved in the study: 96.6 percent for subjects 50 to 59 years old, 97.4 percent for subjects 60 to 69 years old, 97.6 percent for subjects age 60 or over and 98 percent for subjects age 70 or over.
“We are extremely encouraged that the results may point out a health benefit in the prevention of shingles,” Chairman of Global Vaccines at GSK Dr. Moncef Slaoui said. “This disease can be painful and potentially debilitating for some people and older people are particularly at risk. We look forward to continuing the development of our Zoster program.”
Representatives from GSK presented the data at the 25th Scientific Congress of the European Society of Clinical Microbiology and Infectious diseases (ECCMID), which was held in Copenhagen, Denmark. The study results were also published online in the New England Journal of Medicine.